Clarity Pharmaceuticals Advances Prostate Cancer Radiopharmaceuticals with $178m Cash and US Manufacturing Deal

Robust Cash Position Fuels Commercialisation Drive

Clarity Pharmaceuticals (ASX:CU6) closed the quarter ending 30 June 2026 with a cash reserve of $178.3 million, positioning the clinical-stage radiopharmaceutical company well to advance its pipeline towards market entry. Over 60% of this cash is held in US dollars, a strategic move to hedge against currency volatility amid substantial planned US clinical and commercial expenditures. However, the recent Australian dollar appreciation triggered an unrealised exchange loss of $5.9 million in statutory reporting terms.

US Manufacturing Scale-Up Secures Supply Chain for 64Cu-SAR-bisPSMA

In a pivotal development for its lead diagnostic product, Clarity inked a Commercial Manufacturing Agreement with Nucleus RadioPharma in April 2026. This deal taps into Nucleus’s Rochester, Minnesota facility, capable of producing approximately 50,000 patient doses annually, with future expansion planned at a 47,000 square-foot Spring House, Pennsylvania site slated to open in 2028. Together, these facilities aim to supply up to 600,000 doses per year, covering all US states and select international markets including Europe. This complements existing agreements with SpectronRx, Nusano, and Theragenics, creating a tiered, geographically diversified manufacturing and distribution network designed to meet anticipated commercial-scale demand.

Clinical Trials Validate Superior Diagnostic Performance

Clarity’s 64Cu-SAR-bisPSMA continues to demonstrate enhanced diagnostic capabilities. The Phase II Co-PSMA investigator-initiated trial, led by Prof Louise Emmett at St Vincent’s Hospital Sydney, confirmed that 64Cu-SAR-bisPSMA detects 2.63 times more lesions than the current standard-of-care 68Ga-PSMA-11 PET/CT in patients with biochemical recurrence (BCR) of prostate cancer. This head-to-head study, published in European Urology and selected as a Top Rated Oral Presentation at the upcoming EANM Annual Congress 2026, also showed that 64Cu-SAR-bisPSMA led to significant changes in patient management, with 44% of patients having their treatment plans altered following imaging.

The registrational Phase III AMPLIFY trial, which evaluates 64Cu-SAR-bisPSMA PET imaging in BCR patients, completed recruitment in March 2026 with 232 participants dosed and imaged across the US and Australia. Similarly, the CLARIFY Phase III trial, assessing 64Cu-SAR-bisPSMA in high-risk prostate cancer patients prior to prostatectomy, continues recruitment with completion expected this year. These trials aim to provide the data package required for US FDA approval.

Theranostic SECuRE Trial Yields Promising Outcomes

The SECuRE Phase I/IIa trial, investigating theranostic use of 64Cu/67Cu-SAR-bisPSMA in metastatic castration-resistant prostate cancer (mCRPC), is progressing into its Cohort Expansion Phase. Notably, five participants have achieved undetectable disease by radiographic assessment following 67Cu-SAR-bisPSMA treatment, with case reports accepted for presentation at EANM 2026. The trial continues to demonstrate a favourable safety profile and encouraging efficacy, supporting plans for a registrational Phase III study.

Board and Team Strengthened Ahead of Commercial Launch

Reflecting its transition towards commercialisation, Clarity appointed Allison Rossiter as an Independent Non-Executive Director in July 2026. Rossiter brings 25 years of global healthcare leadership experience, including senior roles at Roche and Novartis. Concurrently, Executive Director Dr Colin Biggin stepped down from the Board but remains Chief Operating Officer, maintaining operational continuity. The company’s workforce has expanded by approximately 45% this financial year, surpassing 100 employees with a focus on US and Australian markets, underscoring its commitment to building world-class expertise in radiopharmaceuticals.

Fast Track Status and Regulatory Progress

Clarity holds three US FDA Fast Track Designations for its SAR-bisPSMA products: one for the 67Cu therapeutic agent in mCRPC patients previously treated with androgen receptor pathway inhibitors, and two for the 64Cu diagnostic agent in imaging PSMA-positive prostate cancer lesions in patients with suspected metastasis or biochemical recurrence. These designations facilitate expedited development and regulatory review, reflecting the potential clinical impact of Clarity’s products.

Financials and Operating Cash Flow

Operating cash outflows for the quarter totalled $19.3 million, aligned with expectations as Clarity advances its Phase III trials and theranostic studies. The company received a $9.7 million Research and Development Tax Incentive refund during the period. Payments to related parties, including director fees and salaries, amounted to $727,199. Clarity's cash runway is estimated at nine quarters based on current burn rates, supporting its path through pivotal clinical milestones and towards commercial launch.